BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/25/2017 10:25:05 AM | Browse: 1097 | Download: 1546
 |
Received |
|
2017-04-12 09:08 |
|
Peer-Review Started |
|
2017-04-12 18:18 |
|
To Make the First Decision |
|
2017-05-22 04:03 |
|
Return for Revision |
|
2017-05-23 09:19 |
|
Revised |
|
2017-06-20 18:12 |
|
Second Decision |
|
2017-06-22 02:14 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2017-07-03 02:40 |
|
Articles in Press |
|
2017-07-03 02:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-07-16 13:20 |
|
Publish the Manuscript Online |
|
2017-07-25 10:25 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Chemotherapy for hepatocellular carcinoma: The present and the future
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marco Le Grazie, Maria Rosa Biagini, Mirko Tarocchi, Simone Polvani and Andrea Galli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andrea Galli, MD, PhD, Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences “Mario Serio, University of Florence, Viale Pieraccini 6, Florence 50139, Italy. a.galli@dfc.unifi.it |
| Key Words |
Hepatocellular carcinoma; Systemic therapy; Chemotherapy; Molecular targeted therapy; Cytotoxic therapy; Immunotherapy; Perspectives |
| Core Tip |
The aim of this review is to make a point on chemotherapeutic options for treatment of hepatocellular carcinoma (HCC) at advanced stage, the most frequent stage of presentation of this neoplasia, still characterized by an important mortality rate. By now, sorafenib is the only standard treatment, but other options were recently studied and will be soon available for clinicians and patients affected by HCC. The review can be divided in four sections: The first one regards molecular target therapy and are described sorafenib, its open issues, but also other drugs with similar targets that have been evaluated for treatment of HCC. The second and the third parts regard cytotoxic drugs and immunotherapy, respectively, which were evaluated in recent years as possible alternatives or adjuvant to Sorafenib. In the last part of the review, future perspectives are described, in particular for what concerns resistance mechanism of the neoplasia, delivery methods or biological enhancers for drugs already in use, new drugs that will be probably evaluated and molecular targets that could soon become eligible for target therapy hopefully leading to the development of personalized therapy. |
| Publish Date |
2017-07-25 10:25 |
| Citation |
Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 |
| URL |
http://www.wjgnet.com/1948-5182/full/v9/i21/907.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v9.i21.907 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
